Novoste - 500 Beiträge pro Seite

[cineman]

Weiß jemand, wann Novoste die Q3-Zahlen herausbringt??

cineman

[desastermaster]

Hallo,
die Q3 Zahlen gabs schon am 18.Okt.
Waren soweit ganz gut.
Infos findet man auf der Firmenwebsite
www.novoste.com

Best
dm

NORCROSS, Ga., Oct 18, 2001 (BW HealthWire) --
Record Sales of $20.9 Million Achieved

Novoste Corporation (NASDAQ: NOVT) today reported that for the first time in its history, the Company achieved profitability for the third quarter ended September 30, 2001, reporting net income of $2.1 million, or $0.13 per share.
For the same period last year, Novoste recorded a loss of $8.7 million, or $(0.54) per share.

Also for the quarter, Novoste reported record sales of $20.9 million, compared to sales of $1.4 million for the year ago quarter, prior to the U.S. launch of the Beta-Cath(TM) System. Third quarter sales increased by 21% compared to sales of $17.3 million in the second quarter of 2001.

For the nine-month period ended September 30, 2001, Novoste reported net sales of $47.5 million, a more than 12-fold increase compared to revenue of $3.6 million during the first nine months of 2000. The net loss for the nine-month period was $7.8 million, or $(0.49) per share, compared to a net loss of $23.0 million, or $(1.50) per share for the corresponding period in 2000.

Subject to continuing success of the U.S. launch of the Beta-Cath(TM) System, Novoste estimates that net revenue will range between $23 and $25 million for the fourth quarter ending December 31, 2001. At this revenue level, Novoste Corporation expects to have its second profitable quarter with earnings per share projected to be between $0.20 and $0.25 per share. For the full year ending December 31, 2001, Novoste projects that revenue will reach between $70 and $73 million, and earnings per share will be between $(0.28) per share and $(0.22) per share. For the full year ending December 31, 2002, Novoste projects that revenue will reach between $95 and $110 million, and earnings per share will be between $1.20 and $1.60 per share.

Commenting on the third quarter, William A. Hawkins, President and CEO, said, "I am very proud to report Novoste`s first profitable quarter and its 11th consecutive quarter of revenue growth. The Beta-Cath(TM) System is now in almost 300 hospitals in the U.S., and we expect this number to grow with the backlog of radiation license amendments in process and the interest expressed by hospitals that have yet to initiate vascular brachytherapy programs. Our success reflects the wide acceptance of radiation and its demonstrated efficacy in patient outcomes as we continue to hear anecdotal reports of excellent clinical results from many U.S. centers who now use vascular brachytherapy as the standard of care for the treatment of patients with in-stent restenosis."

Mr. Hawkins continued, "In the near term, we expect product line extensions and U.S. reimbursement both for the hospital and the interventional cardiologist to drive continued growth in our business. In the longer term, we look to leverage our technology into new markets such as the use of radiation to treat peripheral arterial disease and leverage our distribution with new products and technologies to further contribute to our growth."

[cineman]

Novoste hält weiter seinen guten aufwärtstrend nach dieser Analystenmeinung bei.

Princeton, New Jersey, Nov. 6 (Bloomberg Data) -- Novoste Corporation (NOVT US) was reiterated ``buy`` by analyst Mark Landy at Leerink Swann & Co. The 12-month target price is $28.00 per share.

mal sehn
cineman

[desastermaster]

Hallo,
der Inhalt dieser Nachricht koennte sich mittel- bis
langfristig negativ auf das Umsatzpotential von NOVT
auswirken. Ein neues Konkurrenzprodukt und eine
Analystenmeinung, dass die Entwicklung nichtverklebender
Stents die Strahlentherapie teilweise ueberfluessig
macht.

Best
dm

11/05 09:08

By Susan Kelly

CHICAGO, Nov 5 (Reuters) - Medical device maker Guidant Corp. (GDT) said on Monday it has received U.S. regulatory approval to market a radiation treatment to open coronary arteries that have reclogged after stent surgery, its first entry into the market for intravascular radiation therapy.

Indianapolis-based Guidant said it received approval from the U.S. Food and Drug Administration on Friday and that it would begin shipping the device to hospitals immediately.

Rival medical device makers Novoste Corp. (NOVT) and Johnson & Johnson (JNJ) already produce radiation-based treatments for reclogged arteries.

But Guidant`s treatment, named Galileo, is an important development for the company because radiation is now the only way to treat blockages that occur following stent implantation, analysts said.

A stent is a tiny wire-mesh tube surgically implanted into a clogged artery to prop it open. But the artery becomes blocked again in up to 25 percent of stent recipients, a condition called in-stent restenosis.

Shares of Guidant rose $1.85, or 4.39 percent, to end at $43.95 Monday on the New York Stock Exchange. Guidant stock has been trading at its highest level in more than six months.

Guidant`s share price is benefiting from the company`s new products, including the radiation-based artery treatment and a drug-coated stent under development, said Banc of America Securities analyst Kurt Kruger.

"The company is making good progress on the coated-stent front. There is a general attitude of progress across a lot of different areas," he said.

Guidant, Johnson & Johnson and Boston Scientific Corp. (BSX), among other companies, are in a race to bring to market drug-coated stents, which hold the promise of preventing blockages from reoccurring and could eliminate the need for follow-up radiation therapy after the stent is implanted.

Shares of Johnson & Johnson fell 50 cents, or less than 1 percent, to close at $58.48. Novoste shares rose 56 cents, or 4.84 percent, to $12.12. Boston Scientific`s stock gained 48 cents, or 2.02 percent, to $24.27.

Guidant claims its Galileo Intravascular Radiotherapy System is safer and easier to use and can stop blockages from reoccurring in a broader range of patients. The system delivers low doses of radiation through a catheter to dissolve the plaque in the diseased portion of the artery.

Merrill Lynch analyst Daniel Lemaitre said that while the market for intravascular radiation therapy remains robust, the opportunity may be short-lived because drug-coated stents are expected to become available in Europe in 2002 and in the United States in 2003.

"With the advent of drug-eluting stents from (Johnson & Johnson) and others, the market opportunity for in-stent restenosis will likely decline," Lemaitre wrote in a research note.





REUTERS